Should I buy or sell CVRx stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CVRx in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CVRX shares. View CVRX analyst ratings or view top-rated stocks .

What is CVRx's stock price target for 2024?

3 brokerages have issued 1-year price objectives for CVRx's shares. Their CVRX share price targets range from $32.00 to $36.00. On average, they predict the company's share price to reach $33.67 in the next twelve months. This suggests a possible upside of 120.6% from the stock's current price. View analysts price targets for CVRX or view top-rated stocks among Wall Street analysts .

How have CVRX shares performed in 2024?

CVRx's stock was trading at $31.44 at the beginning of the year. Since then, CVRX shares have decreased by 51.5% and is now trading at $15.26. View the best growth stocks for 2024 here .

When is CVRx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 30th 2024. View our CVRX earnings forecast .

How can I listen to CVRx's earnings call?

CVRx will be holding an earnings conference call on Tuesday, April 30th at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link .

How were CVRx's earnings last quarter?

CVRx, Inc. (NASDAQ:CVRX) announced its earnings results on Thursday, January, 25th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.55) by $0.11. The company had revenue of $11.31 million for the quarter, compared to analyst estimates of $10.90 million. CVRx had a negative net margin of 104.85% and a negative trailing twelve-month return on equity of 47.30%.

What guidance has CVRx issued on next quarter's earnings?

CVRx updated its first quarter 2024 earnings guidance on Friday, January, 26th. The company provided EPS guidance of for the period. The company issued revenue guidance of $11.0 million-$12.0 million, compared to the consensus revenue estimate of $11.6 million.

CVRx (CVRX) raised $100 million in an initial public offering on Wednesday, June 30th 2021. The company issued 6,250,000 shares at $15.00-$17.00 per share.

Who are CVRx's major shareholders?

CVRx's stock is owned by a variety of retail and institutional investors. Top institutional investors include GSG Advisors LLC (0.17%). Insiders that own company stock include & Johnson Johnson, Kirk G Nielsen , Mudit K Jain , Nea Partners 10 L P and Paul Verrastro. View institutional ownership trends .

How do I buy shares of CVRx?

Shares of CVRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:CVRX

CVRx (CVRX) Stock Price, News & Analysis

→ New crypto project uncovers 2,050% in 65 days (From InvestorPlace) (Ad)

Free CVRX Stock Alerts

$15.10

-0.16 (-1.05%)

(As of 11:39 AM ET)

Compare

Today's Range: $14.94
▼
$15.57
50-Day Range: $15.26
▼
$24.37
52-Week Range: $9.07
▼
$33.13

Volume: 35,084 shs
Average Volume: 143,800 shs
Market Capitalization: $326.01 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $33.67

Get CVRx alerts:

CVRx MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 120.6% Upside
$33.67 Price Target
Short Interest: Bearish
8.92% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.69
Based on 3 Articles This Week
Insider Trading: Selling Shares
$151,903 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($1.89) to ($1.53) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.40 out of 5 stars

Medical Sector

491st out of 918 stocks

Surgical & Medical Instruments Industry

55th out of 97 stocks

3.5

Analyst's Opinion

Consensus Rating
CVRx has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
CVRx has only been the subject of 2 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
8.92% of the float of CVRx has been sold short.
Short Interest Ratio / Days to Cover
CVRx has a short interest ratio ("days to cover") of 5.5.
Change versus previous month
Short interest in CVRx has recently increased by 6.34%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
CVRx does not currently pay a dividend.
Dividend Growth
CVRx does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CVRX.

3.2

News and Social Media Coverage

News Sentiment
CVRx has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for CVRx this week, compared to 2 articles on an average week.
Search Interest
4 people have searched for CVRX on MarketBeat in the last 30 days.
MarketBeat Follows
Only 2 people have added CVRx to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, CVRx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $151,903.00 in company stock.
Percentage Held by Insiders
18.30% of the stock of CVRx is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
75.27% of the stock of CVRx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for CVRx are expected to grow in the coming year, from ($1.89) to ($1.53) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of CVRx is -7.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of CVRx is -7.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
CVRx has a P/B Ratio of 4.18. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

About CVRx Stock (NASDAQ:CVRX)

CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

CVRX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CVRX Stock News Headlines

April 16, 2024 | finance.yahoo.com

CVRx to Report First Quarter 2024 Financial and Operating Results and Host Conference Call on April 30th, 2024

April 15, 2024 | globenewswire.com

CVRx announces availability of additional data supporting long-term benefits of Barostim

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 15, 2024 | globenewswire.com

CVRx announces availability of additional data supporting long-term benefits of Barostim

March 28, 2024 | fool.com

What Companies Does Johnson & Johnson Own?

March 21, 2024 | bizjournals.com

Target to double bonuses for salaried employees in signal of profit growth

March 18, 2024 | markets.businessinsider.com

Craig-Hallum Reaffirms Their Hold Rating on ProSomnus (OSA)

February 25, 2024 | msn.com

CVRx (CVRX) Price Target Increased by 10.54% to 33.15

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

February 17, 2024 | finance.yahoo.com

CVRX Mar 2024 30.000 call

February 17, 2024 | finance.yahoo.com

CVRX Mar 2024 20.000 put

February 2, 2024 | finance.yahoo.com

CVRx names Kevin Hykes as CEO

February 1, 2024 | markets.businessinsider.com

Piper Sandler Keeps Their Buy Rating on CVRx (CVRX)

February 1, 2024 | msn.com

CVRx Names Kevin Hykes as New President and CEO

January 31, 2024 | finance.yahoo.com

CVRx Full Year 2023 Earnings: EPS Beats Expectations

January 31, 2024 | finanznachrichten.de

CVRx, Inc.: CVRx Announces Appointment of Kevin Hykes as President and Chief Executive Officer

January 31, 2024 | marketwatch.com

CVRx Names Board Member Kevin Hykes President, CEO

January 31, 2024 | finance.yahoo.com

CVRx Announces Appointment of Kevin Hykes as President and Chief Executive Officer

January 31, 2024 | markets.businessinsider.com

Bio-Techne (TECH) Receives a Buy from Craig-Hallum

January 28, 2024 | finance.yahoo.com

CVRx, Inc. (NASDAQ:CVRX) Q4 2023 Earnings Call Transcript

January 26, 2024 | finanznachrichten.de

CVRx, Inc.: CVRx Reports Fourth Quarter and Full Year 2023 Financial and Operating Results

January 26, 2024 | finance.yahoo.com

Q4 2023 CVRx Inc Earnings Call

January 25, 2024 | benzinga.com

CVRx: Q4 Earnings Insights

January 25, 2024 | finance.yahoo.com

CVRx Reports Fourth Quarter and Full Year 2023 Financial and Operating Results

January 25, 2024 | finance.yahoo.com

CVRx Inc (CVRX) Reports Substantial Revenue Growth in 2023

January 24, 2024 | benzinga.com

Earnings Outlook For CVRx

January 22, 2024 | finance.yahoo.com

CVRx (CVRX) Upgraded to Strong Buy: What Does It Mean for the Stock?

See More Headlines

Receive CVRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CVRx and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 1/25/2024
Today: 4/19/2024
Next Earnings (Confirmed): 4/30/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Surgical & medical instruments
Sub-Industry: N/A
Current Symbol: NASDAQ:CVRX
CUSIP: N/A
CIK: 1235912
Web: www.cvrx.com
Phone: 763-416-2840
Fax: 763-416-2841
Employees: 200
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $33.67
High Stock Price Target: $36.00
Low Stock Price Target: $32.00
Potential Upside/Downside: +117.8%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.98)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-41,200,000.00
Net Margins: -104.85%
Pretax Margin: -104.47%
Return on Equity: -47.30%
Return on Assets: -35.88%

Debt

Debt-to-Equity Ratio: 0.38
Current Ratio: 14.25
Quick Ratio: 12.86

Sales & Book Value

Annual Sales: $39.29 million
Price / Sales: 8.50
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.65 per share
Price / Book: 4.24

Miscellaneous

Outstanding Shares: 21,590,000
Free Float: 17,643,000
Market Cap: $333.78 million
Optionable: Optionable
Beta: 1.29

5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

Mr. Kevin Hykes (Age 58)
President, CEO & Director
Mr. Jared Oasheim (Age 40)
Chief Financial Officer
Comp: $446.1k
Mr. Paul Verrastro (Age 61)
Chief Marketing & Strategy Officer
Comp: $529.84k
Mr. Paul Pignato
Vice President of Operations
Ms. Jonelle R. Burnham (Age 53)
Vice President & General Counsel
Mr. Craig Palmer (Age 47)
Senior Vice President of US Sales

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CVRX Stock Analysis - Frequently Asked Questions

Should I buy or sell CVRx stock right now?: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CVRx in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CVRX shares.
View CVRX analyst ratings or view top-rated stocks.
What is CVRx's stock price target for 2024?: 3 brokerages have issued 1-year price objectives for CVRx's shares. Their CVRX share price targets range from $32.00 to $36.00. On average, they predict the company's share price to reach $33.67 in the next twelve months. This suggests a possible upside of 120.6% from the stock's current price.
View analysts price targets for CVRX or view top-rated stocks among Wall Street analysts.
How have CVRX shares performed in 2024?: CVRx's stock was trading at $31.44 at the beginning of the year. Since then, CVRX shares have decreased by 51.5% and is now trading at $15.26.
View the best growth stocks for 2024 here.
When is CVRx's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 30th 2024.
View our CVRX earnings forecast.
How can I listen to CVRx's earnings call?: CVRx will be holding an earnings conference call on Tuesday, April 30th at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link.
How were CVRx's earnings last quarter?: CVRx, Inc. (NASDAQ:CVRX) announced its earnings results on Thursday, January, 25th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.55) by $0.11. The company had revenue of $11.31 million for the quarter, compared to analyst estimates of $10.90 million. CVRx had a negative net margin of 104.85% and a negative trailing twelve-month return on equity of 47.30%.

What guidance has CVRx issued on next quarter's earnings?: CVRx updated its first quarter 2024 earnings guidance on Friday, January, 26th. The company provided EPS guidance of for the period. The company issued revenue guidance of $11.0 million-$12.0 million, compared to the consensus revenue estimate of $11.6 million.
When did CVRx IPO?: CVRx (CVRX) raised $100 million in an initial public offering on Wednesday, June 30th 2021. The company issued 6,250,000 shares at $15.00-$17.00 per share.
Who are CVRx's major shareholders?: CVRx's stock is owned by a variety of retail and institutional investors. Top institutional investors include GSG Advisors LLC (0.17%). Insiders that own company stock include & Johnson Johnson, Kirk G Nielsen, Mudit K Jain, Nea Partners 10 L P and Paul Verrastro.
View institutional ownership trends.
How do I buy shares of CVRx?: Shares of CVRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CVRX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial